On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.

On February 20, 2024, a significant filing was made with the United States Securities and Exchange Commission (SEC) by New Dimensions Trading Ltd. and Jacob Safier, reporting a collective beneficial ownership of 350,000 shares of T2 Biosystems, Inc. This stake represents 7.1% of the company, based on the total number of shares outstanding as reported in T2 Biosystems' Proxy Statement filed on March 4, 2024. The filing, made under Schedule 13G, indicates that neither New Dimensions Trading Ltd. nor Jacob Safier, who may be deemed to beneficially own the shares due to his role as portfolio manager, have acquired the shares with the intent to change or influence the control of T2 Biosystems. The filing was certified as true and correct by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier on March 11, 2024. The joint filing agreement also indicates that any amendments to the Schedule 13G statement will be filed on behalf of both parties.